<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_enterococcus" title="Novel Small-molecule Antibacterials against Gram-positive Pathogens of Staphylococcus and Enterococcus Species" shortTitle="enterococcus" author="Marius Seethaler, Tobias Hertlein, BjÃ¶rn Wecklein, Alba Ymeraj, Knut Ohlsen, Michael Lalk, Andreas Hilgeroth" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/2079-6382/8/4/210/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
1.	LS	1.
Introduction	NN	introduction
</s>
</head>
<p>
<s type="decl">
The	DT	the
increasing	VBG	increase
resistances	NNS	resistance
of	IN	of
pathogenic	JJ	pathogenic
bacteria	NNS	bacteria
are	VBP	be
one	CD	one
great	JJ	great
problem	NN	problem
for	IN	for
worldwide	JJ	worldwide
health	NN	health
policy	NN	policy
,	,	,
because	IN	because
it	PRP	it
means	VBZ	mean
a	DT	a
threat	NN	threat
of	IN	of
humanity	NN	humanity
.	.	.
</s>
<s type="decl">
Pathogenic	JJ	Pathogenic
bacteria	NNS	bacteria
can	MD	can
be	VB	be
found	VBN	find
in	IN	in
human	JJ	human
surroundings	NNS	surroundings
,	,	,
and	CC	and
drinking	NN	drinking
water	NN	water
may	MD	may
be	VB	be
contaminated	VBN	contaminate
with	IN	with
bacteria	NN	bacteria
in	IN	in
developing	VBG	develop
countries	NNS	country
.	.	.
</s>
<s type="decl">
In	IN	in
the	DT	the
last	JJ	last
century	NN	century
sufficient	JJ	sufficient
antibacterials	NNS	antibacterial
were	VBD	be
available	JJ	available
to	TO	to
effectively	RB	effectively
treat	VB	treat
infections	NNS	infection
with	IN	with
those	DT	this
various	JJ	various
bacteria	NNS	bacteria
.	.	.
</s>
<s type="decl">
Beside	IN	beside
the	DT	the
standard	JJ	standard
antibacterials	NNS	antibacterial
like	IN	like
penicillin	NN	penicillin
,	,	,
reserve	NN	reserve
antibiotics	NNS	antibiotics
have	VBP	have
been	VBN	be
discovered	VBN	discover
from	IN	from
natural	JJ	natural
sources	NNS	source
and	CC	and
were	VBD	be
resynthesized	VBN	resynthesize
by	IN	by
industrial	JJ	industrial
companies	NNS	company
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
an	DT	a
abuse	NN	abuse
and	CC	and
overuse	NN	overuse
of	IN	of
those	DT	this
antibiotics	NNS	antibiotics
is	VBZ	be
one	CD	one
of	IN	of
the	DT	the
reasons	NNS	reason
for	IN	for
the	DT	the
present	JJ	present
crisis	NN	crisis
with	IN	with
resistant	JJ	resistant
bacteria	NNS	bacteria
.	.	.
</s>
<s type="decl">
In	IN	in
the	DT	the
case	NN	case
of	IN	of
viral	JJ	viral
infections	NNS	infection
,	,	,
antibiotics	NNS	antibiotics
are	VBP	be
often	RB	often
prescribed	VBN	prescribe
.	.	.
</s>
<s type="decl">
In	IN	in
the	DT	the
case	NN	case
of	IN	of
existing	VBG	exist
sensitivities	NNS	sensitivity
of	IN	of
bacteria	NNS	bacteria
towards	IN	towards
standard	JJ	standard
antibiotics	NNS	antibiotics
,	,	,
novel	NN	novel
reserve	NN	reserve
antibiotics	NNS	antibiotics
have	VBP	have
been	VBN	be
used	VBN	use
in	IN	in
clinics	NNS	clinic
.	.	.
</s>
<s type="decl">
Therefore	RB	therefore
,	,	,
bacteria	NNS	bacteria
with	IN	with
contact	NN	contact
to	IN	to
those	DT	this
antibiotics	NNS	antibiotics
like	IN	like
<hi rend="italic">
Staphylococcus	NNP	Staphylococcus
aureus	NN	aureus
</hi>
on	IN	on
human	JJ	human
surfaces	NNS	surface
like	IN	like
skin	NN	skin
developed	VBD	develop
early	JJ	early
resistances	NNS	resistance
.	.	.
</s>
<s type="decl">
A	DT	a
misuse	NN	misuse
of	IN	of
antibiotics	NNS	antibiotics
is	VBZ	be
also	RB	also
present	JJ	present
in	IN	in
the	DT	the
mast	NN	mast
of	IN	of
poultry	NN	poultry
.	.	.
</s>
<s type="decl">
Those	DT	this
antibiotics	NNS	antibiotics
contaminate	VBP	contaminate
the	DT	the
environment	NN	environment
by	IN	by
animal	NN	animal
excretions	NNS	excretion
.	.	.
</s>
<s type="decl">
Finally	RB	finally
,	,	,
industrial	JJ	industrial
waste	NN	waste
of	IN	of
antibiotic	JJ	antibiotic
production	NN	production
is	VBZ	be
pumped	VBN	pump
into	IN	into
rivers	NNS	river
in	IN	in
producing	VBG	produce
countries	NNS	country
like	IN	like
India	NNP	India
.	.	.
</s>
<s type="decl">
Moreover	RB	moreover
,	,	,
bacteria	NNS	bacteria
develop	VBP	develop
resistance	NN	resistance
mechanisms	NNS	mechanism
that	WDT	that
allow	VBP	allow
the	DT	the
spread	NN	spread
of	IN	of
resistance	NN	resistance
genes	NNS	gene
via	IN	via
plasmids	NNS	plasmid
,	,	,
and	CC	and
also	RB	also
between	IN	between
different	JJ	different
species	NNS	species
.	.	.
</s>
<s type="decl">
One	CD	one
other	JJ	other
problem	NN	problem
that	WDT	that
contributes	VBZ	contribute
to	IN	to
the	DT	the
present	JJ	present
antibiotic	JJ	antibiotic
crisis	NN	crisis
is	VBZ	be
the	DT	the
fact	NN	fact
that	IN	that
pharmaceutical	JJ	pharmaceutical
companies	NNS	company
recently	RB	recently
announced	VBD	announce
that	IN	that
they	PRP	they
would	MD	would
no	RB	no
longer	RBR	long
invest	VB	invest
in	IN	in
the	DT	the
development	NN	development
of	IN	of
novel	JJ	novel
antibiotics	NNS	antibiotics
.	.	.
</s>
<s type="decl">
The	DT	the
financial	JJ	financial
outcome	NN	outcome
of	IN	of
the	DT	the
development	NN	development
of	IN	of
life	NN	life
style	NN	style
drugs	NNS	drug
is	VBZ	be
much	RB	much
better	JJR	good
than	IN	than
that	DT	that
of	IN	of
antibiotics	NNS	antibiotics
.	.	.
</s>
<s type="decl">
Antibiotics	NNS	antibiotics
have	VBP	have
to	TO	to
be	VB	be
cheap	JJ	cheap
for	IN	for
a	DT	a
use	NN	use
in	IN	in
low-income	JJ	low-income
or	CC	or
developing	VBG	develop
countries	NNS	country
.	.	.
</s>
<s type="decl">
Innovative	JJ	innovative
but	CC	but
vague	JJ	vague
approaches	NNS	approach
to	TO	to
find	VB	find
novel	JJ	novel
antibiotics	NNS	antibiotics
have	VBP	have
been	VBN	be
an	DT	a
influencing	NN	influencing
of	IN	of
the	DT	the
bacterial	JJ	bacterial
gene	NN	gene
expression	NN	expression
to	TO	to
modify	VB	modify
the	DT	the
bacterial	JJ	bacterial
metabolism	NN	metabolism
.	.	.
</s>
<s type="sub">
Such	PDT	such
a	DT	a
modified	VBN	modify
metabolism	NN	metabolism
might	MD	might
lead	VB	lead
to	IN	to
novel	JJ	novel
metabolic	JJ	metabolic
products	NNS	product
which	WDT	which
have	VBP	have
to	TO	to
be	VB	be
identified	VBN	identify
and	CC	and
tested	VBN	test
for	IN	for
their	PRP$	their
antibacterial	JJ	antibacterial
properties	NNS	property
.	.	.
</s>
<s type="sub">
Methods	NNS	method
to	TO	to
alter	VB	alter
gene	NN	gene
expression	NN	expression
may	MD	may
be	VB	be
varied	VBN	vary
growth	NN	growth
conditions	NNS	condition
or	CC	or
a	DT	a
microbial	JJ	microbial
co-culturing	NN	co-culturing
of	IN	of
various	JJ	various
bacteria	NNS	bacteria
or	CC	or
of	IN	of
fungi	NNS	fungi
and	CC	and
bacteria	NNS	bacteria
.	.	.
</s>
<s type="decl">
Other	JJ	other
sources	NNS	source
for	IN	for
the	DT	the
identification	NN	identification
of	IN	of
novel	JJ	novel
antibiotics	NNS	antibiotics
have	VBP	have
been	VBN	be
plants	NNS	plant
,	,	,
marine	JJ	marine
invertebrates	NNS	invertebrate
and	CC	and
insects	NNS	insect
or	CC	or
amphibia	NNS	amphibia
.	.	.
</s>
<s type="decl">
Isolated	VBN	isolate
antimicrobial	JJ	antimicrobial
peptides	NNS	peptide
from	IN	from
such	JJ	such
sources	NNS	source
have	VBP	have
long	RB	long
been	VBN	be
favored	VBN	favor
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
they	PRP	they
still	RB	still
hamper	VBP	hamper
with	IN	with
various	JJ	various
problems	NNS	problem
like	IN	like
proteolytic	JJ	proteolytic
instability	NN	instability
,	,	,
short	JJ	short
in	IN	in
vivo	NN	vivo
half-lives	NNS	half-live
,	,	,
insufficient	JJ	insufficient
solubility	NN	solubility
and	CC	and
a	DT	a
poor	JJ	poor
bioavailability	NN	bioavailability
.	.	.
</s>
</p>
<p>
<s type="decl">
Alternative	JJ	alternative
small-molecule	NN	small-molecule
antibacterials	NNS	antibacterial
are	VBP	be
rare	JJ	rare
.	.	.
</s>
<s type="decl">
They	PRP	they
own	VBP	own
promising	JJ	promising
properties	NNS	property
for	IN	for
an	DT	a
oral	JJ	oral
use	NN	use
,	,	,
and	CC	and
are	VBP	be
not	RB	not
expected	VBN	expect
to	TO	to
show	VB	show
problems	NNS	problem
reported	VBN	report
for	IN	for
those	DT	this
antimicrobial	JJ	antimicrobial
peptides	NNS	peptide
.	.	.
</s>
<s type="decl">
Presently	RB	presently
,	,	,
such	JJ	such
small-molecule	JJ	small-molecule
antibacterials	NNS	antibacterial
that	WDT	that
result	VBP	result
from	IN	from
synthetic	JJ	synthetic
chemistry	NN	chemistry
are	VBP	be
unknown	JJ	unknown
to	TO	to
emerge	VB	emerge
as	IN	as
a	DT	a
novel	JJ	novel
antibacterial	JJ	antibacterial
compound	NN	compound
class	NN	class
.	.	.
</s>
</p>
<p>
<s type="decl">
We	PRP	we
gained	VBD	gain
access	NN	access
to	IN	to
two	CD	2
novel	JJ	novel
structurally-related	JJ	structurally-related
classes	NNS	class
of	IN	of
small-molecule	JJ	small-molecule
antibacterials	NNS	antibacterial
by	IN	by
the	DT	the
reaction	NN	reaction
of	IN	of
substituted	VBN	substitute
indoles	NNS	indole
and	CC	and
thiophene	NN	thiophene
dicarbaldehyde	NN	dicarbaldehyde
.	.	.
</s>
<s type="decl">
Therefore	RB	therefore
,	,	,
various	JJ	various
composed	VBN	compose
hybrid	JJ	hybrid
molecules	NNS	molecule
were	VBD	be
yielded	VBN	yield
from	IN	from
those	DT	this
indoles	NNS	indole
and	CC	and
benzothiophene	NN	benzothiophene
.	.	.
</s>
<s type="decl">
Hybrid	JJ	hybrid
molecules	NNS	molecule
of	IN	of
antimicrobial	JJ	antimicrobial
active	JJ	active
antibiotics	NNS	antibiotics
,	,	,
or	CC	or
antifungal	JJ	antifungal
drugs	NNS	drug
have	VBP	have
recently	RB	recently
been	VBN	be
reviewed	VBN	review
.	.	.
</s>
<s type="decl">
They	PRP	they
mostly	RB	mostly
consist	VBP	consist
either	CC	either
of	IN	of
two	CD	2
different	JJ	different
antibiotics	NNS	antibiotics
or	CC	or
antifungals	NNS	antifungal
that	WDT	that
are	VBP	be
connected	VBN	connect
by	IN	by
a	DT	a
linker	NN	linker
like	IN	like
a	DT	a
simple	JJ	simple
carbon	NN	carbon
chain	NN	chain
.	.	.
</s>
<s type="decl">
So	RB	so
fluoroquinolone-oxazolidinone	JJ	fluoroquinolone-oxazolidinone
hybrids	NNS	hybrid
reached	VBD	reach
clinical	JJ	clinical
trials	NNS	trial
and	CC	and
novel	NN	novel
1	CD	1
,	,	,
2	CD	2
,	,	,
3-triazole	CD	3-triazole
antifungal	JJ	antifungal
hybrids	NNS	hybrid
with	IN	with
8-aminoquinoline	NN	8-aminoquinoline
or	CC	or
dioxolane	NN	dioxolane
have	VBP	have
recently	RB	recently
been	VBN	be
reported	VBN	report
.	.	.
</s>
</p>
<p>
<s type="decl">
Our	PRP$	our
novel	NN	novel
compound	NN	compound
classes	NNS	class
were	VBD	be
tested	VBN	test
against	IN	against
prominent	JJ	prominent
Gram-positive	JJ	Gram-positive
bacteria	NNS	bacteria
that	WDT	that
are	VBP	be
associated	VBN	associate
with	IN	with
severe	JJ	severe
hospital	NN	hospital
infections	NNS	infection
by	IN	by
<hi rend="italic">
Staphylococcus	NNP	Staphylococcus
</hi>
and	CC	and
<hi rend="italic">
Enterococcus	NNP	Enterococcus
</hi>
strains	NNS	strain
.	.	.
</s>
<s type="decl">
We	PRP	we
identified	VBD	identify
first	JJ	first
lead	NN	lead
compounds	NNS	compound
with	IN	with
promising	JJ	promising
activities	NNS	activity
and	CC	and
confirmed	VBD	confirm
the	DT	the
in	RB	in
vitro	NN	vitro
results	NNS	result
first	RB	first
in	IN	in
the	DT	the
in	IN	in
vivo	NN	vivo
studies	NNS	study
for	IN	for
selected	VBN	select
derivatives	NNS	derivative
.	.	.
</s>
</p>
</text>